This is Part 1 of Shared Decisions, Better Outcome: Collaboration in Managing Targeted Therapy for HR-Positive/HER2-Negative Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Erika Hamilton, MD, Melissa Rikal, MSN, FNP-BC, AOCNP®, and Heather Moore, CPP, PharmD, discuss team-based management of hormone receptor–positive metastatic breast cancer. The patient is a 44-year-old woman with de novo ER/PR-positive, HER2-negative metastatic breast cancer involving the liver, lymph nodes, and bone, who received ovarian suppression and ultimately a bilateral salpingo-oophorectomy prior to presenting with disease progression after 5 years of endocrine therapy plus a CDK4/6 inhibitor.

 

The faculty highlight the importance of mutational testing to identify ESR1 mutations for selecting targeted therapies and explore oral options like elacestrant, imlunestrant, and vepdegestrant, emphasizing patient education for managing side effects. The panel also reviews team-based strategies for patient monitoring, counseling on tolerability, and considerations such as drug interactions and lipid monitoring when initiating therapy.